As we had previously observed the emergence of focal amplifications in the plasma of patients with colorectal cancer under anti-EGFR therapy11, we hypothesized that focal SCNAs may be an efficient means of adapting to selection pressure in prostate cancer as well. The gene discussed is EGFR; the disease is prostate carcinoma.